国内国际同发力,鲁抗医药激活发展新引擎

Core Viewpoint - The company is accelerating its global market expansion and promoting the integration of domestic and international trade, driven by the continuous high-level opening-up of the country and the Belt and Road Initiative, aiming to create a new pattern of coordinated development between domestic and international businesses [1] Group 1: Product Development and R&D - The company is focusing on product line construction around "two key areas and six distinctive products," enhancing full-cycle management and implementing a boutique R&D project, achieving phased results in product structure adjustment [1] - The company is strengthening R&D investment, with breakthroughs in innovative drugs and high-end formulations, expecting two innovative drugs to enter Phase II clinical trials and one to enter Phase I clinical trials by mid-2025 [1] Group 2: Sales and Market Strategy - The company adopts a diversified business model primarily based on agency recruitment for domestic formulations, utilizing a comprehensive sales strategy that includes channel distribution, terminal delivery, academic promotion, and more, to cover most market terminals nationwide [2] - By mid-2025, the sales proportion of new products in the company's formulations increased, with new product sales accounting for 31% of the total formulation sales amount [2] - Significant sales growth was observed in products such as Acarbose tablets, Rosuvastatin calcium tablets, and Dapoxetine hydrochloride, with new products accelerating industrialization and forming new revenue growth points [2] Group 3: Internationalization Strategy - The company is advancing its international strategy by enhancing cooperation with global giants and integrating into international supply chains, aiming to expand overseas markets and drive international marketing [3] - The company achieved a breakthrough in international trade revenue, which is expected to exceed 1 billion yuan for the first time in 2024, with continued growth in the first half of 2025 [3] - The export sales of human formulations are projected to approach 100 million yuan in 2024, demonstrating strong market competitiveness [3] Group 4: Registration and Compliance - The company implements a registration-driven export strategy, planning global layouts for all products and enhancing international registration capabilities, achieving 12 new registration certificates and 10 re-registration certificates in 2024 [4] - The company successfully passed international audits for six formulation production lines and received multiple new approvals and re-registration certificates in the first half of 2025 [4] Group 5: Market Expansion and Opportunities - The company is leveraging the opportunities presented by the Belt and Road Initiative to deepen market penetration in emerging markets such as Africa and Central Asia, with increasing sales [5] - The company aims to enhance the synergy between domestic and international markets, seeking new opportunities and promoting high-quality development through dual circulation [5]